Join NSF International Pharma Biotech CPhI Worldwide for a GMP Deficiencies Discussion

NSF International’s pharma biotech team will be exhibiting at CPhI Worldwide in Madrid, Spain this October.

Taking place from 9 October to 11 October, CPhl is one of the largest pharmaceutical tradeshows worldwide, hosted together with co-located events ICSE, InnoPack, P-MEC and FDF. The event brings together some of the world’s most prominent pharma executives and suppliers for three days of collaboration, information dissemination and discussions that will help to define the future of the industry.

Join the pharma world at this event and come to meet NSF International’s team at stand 3G63. Its experts David Waddington, Catherine Kay and Lynne Byers will be in attendance, discussing good manufacturing practice (GMP) deficiencies. You’ll also learn more about the company’s pharma biotech services, including world-class regulatory and compliance consulting, auditing and training on a global basis.

On 10 October, the previous head of inspectorate and licensing for the MHRA Lynne Byers will present the Managing the Pharmaceutical Supply Chain session at 15:50pm in the ICSE theatre room. In the session, you will learn how pharmaceutical supply chains within the industry have become very complicated with many actors, and how you can use recent legislation to identify and manage risks in these increasingly complex supply chains.

Lynne’s session will also cover how to meet the EU regulatory requirements for active pharmaceutical ingredients (API) supply chains, what needs to be included in the qualified person (QP) declaration, the prominent issue of Brexit, and the potential impact on supply chains.

Lynne Byers will also be attending a closed-door roundtable discussion on 9 October for CEOs and members of executive leadership teams from across the pharmaceutical industry to share ideas and discuss key challenges regarding policy, regulation, industry growth, new markets and global challenges. A write-up will be produced post-event detailing key discussion points and the solutions needed to overcome challenges and create change in pharma.

More About This Company